BANGKOK (NNT) – A trial of a COVID-19 vaccine candidate in monkeys has been successful, with the subjects showing higher immune responses. Researchers are now gearing up for human clinical trials in October, with production starting in mid-2021.

A study of a COVID-19 vaccine prototype in monkeys, performed by the National Research Council of Thailand (NRCT) and Chulalongkorn University’s National Primate Research Center of Thailand, has been successful, according to the NRCT.

This experimental mRNA vaccine had first been successfully tested in rats, while the tests in monkeys started on 23 May.

The Minister of Higher Education, Science, Research and Innovation, Suvit Maesincee, said all the monkeys that received the vaccine show no negative side effects, while their blood tests show a satisfactory level of the antibody triggered by the vaccine.

The monkeys, at the National Primate Research Center, have been injected with the vaccine once. Researchers will today administer the second dose for further study. Should all go well, the clinical trial of this vaccine candidate in humans can begin in October and November this year.

The NRCT Secretary General Dr. Sirirurg Songsivilai said the monkeys will be tested periodically for their immune responses after receiving the second dose of vaccine, with their antibody level expected to increase over the next two weeks, while the third dose will be administered in August.

He said this research project is now progressing on track, with the target to start producing a viable COVID-19 vaccine in Thailand in mid-2021.

The National Primate Research Center Director Suchinda Malaivijitnond said the experimental vaccine has shown no negative side effects in recipient monkeys with no fever, or symptoms in the neurological, cardiovascular, respiratory or digestive systems.

The monkeys are showing normal behaviour, which is a good sign that this vaccine prototype would be safe for use in humans.

She said the project shows the world-class capabilities of vaccine researchers and development projects in Thailand.

About the author

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sign Up for Our Newsletter

Get notified of our weekly selection of news

You May Also Like

SET welcomes dietary supplement manufacturer “NV”

The Stock Exchange of Thailand (SET) will list Nova Organic pcl, a manufacturer of dietary supplements, on December 24 under the ticker symbol “NV”.

Thailand’s Digital Health Pass Now Accepted in EU

Thailand is the second country in the ASEAN region to adopt this common standard for digital certification. Travelers are, however, encouraged to check with their destination countries prior to travel.

Vietnam’s Health Supplement Market: Trends, Opportunities, Market Entry

The growing demand for health supplements has resulted in increased usage of imported products as people tend to trust these brands more than domestic ones. Foreign brands tend to be positioned in the premium segment to attract mid-to-high-end consumers, while local brands generally concentrate on the mass market.